Key Factors and Emerging Trends Shaping the Artificial Pancreas Device System Market Landscape

The artificial pancreas device system market is poised for significant expansion in the coming years, driven by advancements in diabetes technology and increasing demand for automated glucose management solutions. This report explores the market's projected size, key players, emerging trends, and segmentation to provide a comprehensive understanding of this rapidly evolving sector.

Projected Market Size and Growth of the Artificial Pancreas Device System Market
The artificial pancreas device system market is anticipated to grow substantially, reaching a valuation of $3.92 billion by 2030. This represents a compound annual growth rate (CAGR) of 13.7% over the forecast period. The market surge is largely fueled by rising demand for fully automated glucose regulation systems, growing investments in digital diabetes care, expansion of remote patient monitoring capabilities, an increasing emphasis on personalized insulin therapy, and enhanced regulatory support for innovative diabetes management devices. Key market trends include the rising use of closed-loop glucose control systems, greater integration of continuous glucose monitors (CGM) with insulin pumps, expanded application of predictive algorithms for insulin delivery, a broader range of wearable diabetes management tools, and a stronger focus on patient-centered automation.

Download a free sample of the artificial pancreas device system market report:
https://www.thebusinessresearchcompany.com/report/artificial-pancreas-device-system-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Leading Players Driving the Artificial Pancreas Device System Market
Several prominent companies are shaping the artificial pancreas device system market landscape, including Medtronic plc, Abbott Laboratories, DexCom Inc., Insulet Corporation, Tandem Diabetes Care Inc., Roche Diabetes Care, Ypsomed, SOOIL Development, Beta Bionics Inc., Bigfoot Biomedical Inc., Diabeloop SA, Inreda Diabetic B.V., Defymed SAS, DreaMed Diabetes Ltd., Medtrum Technologies Inc., EOFlow Co. Ltd., Cellnovo, Pancreum Inc., Admetsys Corporation, GlucoModicum, and MicroTech Medical.
In a notable development, Abbott Laboratories acquired Bigfoot Biomedical in September 2023 for an undisclosed sum. This acquisition strengthens Abbott's position in diabetes care by leveraging its leading Freestyle Libre continuous glucose monitoring technology. It also advances Abbott's goal of delivering integrated, personalized diabetes management solutions. Bigfoot Biomedical specializes in developing automated insulin delivery systems, commonly referred to as artificial pancreas prototypes.

Emerging Innovations and Trends in the Artificial Pancreas Device System Industry
Companies in this market are increasingly investing in innovative technologies to maintain a competitive edge. For example, the push for automation is evident in advancements like automated viscometers, which measure liquid viscosity without manual intervention. In March 2023, Sofraser, an electronics manufacturer from France, introduced the INVI viscometer. This compact, inline device offers continuous real-time viscosity measurements and is designed for durability and accuracy in challenging industrial environments. Its maintenance-free operation and seamless integration into existing systems enhance process control and efficiency.

The artificial pancreas device system market is poised for significant expansion in the coming years, driven by advancements in diabetes technology and increasing demand for automated glucose management solutions. This report explores the market's projected size, key players, emerging trends, and segmentation to provide a comprehensive understanding of this rapidly evolving sector.

Projected Market Size and Growth of the Artificial Pancreas Device System Market
The artificial pancreas device system market is anticipated to grow substantially, reaching a valuation of $3.92 billion by 2030. This represents a compound annual growth rate (CAGR) of 13.7% over the forecast period. The market surge is largely fueled by rising demand for fully automated glucose regulation systems, growing investments in digital diabetes care, expansion of remote patient monitoring capabilities, an increasing emphasis on personalized insulin therapy, and enhanced regulatory support for innovative diabetes management devices. Key market trends include the rising use of closed-loop glucose control systems, greater integration of continuous glucose monitors (CGM) with insulin pumps, expanded application of predictive algorithms for insulin delivery, a broader range of wearable diabetes management tools, and a stronger focus on patient-centered automation.

Download a free sample of the artificial pancreas device system market report:
https://www.thebusinessresearchcompany.com/report/artificial-pancreas-device-system-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR
Leading Players Driving the Artificial Pancreas Device System Market
Several prominent companies are shaping the artificial pancreas device system market landscape, including Medtronic plc, Abbott Laboratories, DexCom Inc., Insulet Corporation, Tandem Diabetes Care Inc., Roche Diabetes Care, Ypsomed, SOOIL Development, Beta Bionics Inc., Bigfoot Biomedical Inc., Diabeloop SA, Inreda Diabetic B.V., Defymed SAS, DreaMed Diabetes Ltd., Medtrum Technologies Inc., EOFlow Co. Ltd., Cellnovo, Pancreum Inc., Admetsys Corporation, GlucoModicum, and MicroTech Medical.
In a notable development, Abbott Laboratories acquired Bigfoot Biomedical in September 2023 for an undisclosed sum. This acquisition strengthens Abbott's position in diabetes care by leveraging its leading Freestyle Libre continuous glucose monitoring technology. It also advances Abbott's goal of delivering integrated, personalized diabetes management solutions. Bigfoot Biomedical specializes in developing automated insulin delivery systems, commonly referred to as artificial pancreas prototypes.

Emerging Innovations and Trends in the Artificial Pancreas Device System Industry
Companies in this market are increasingly investing in innovative technologies to maintain a competitive edge. For example, the push for automation is evident in advancements like automated viscometers, which measure liquid viscosity without manual intervention. In March 2023, Sofraser, an electronics manufacturer from France, introduced the INVI viscometer. This compact, inline device offers continuous real-time viscosity measurements and is designed for durability and accuracy in challenging industrial environments. Its maintenance-free operation and seamless integration into existing systems enhance process control and efficiency.

Detailed Segmentation Analysis of the Artificial Pancreas Device System Market
This market is divided into several key segments to better understand product offerings and end-user categories:
1) Device Type: Threshold Suspend Device Systems, Control-To-Range Systems, Control-To-Target Systems
2) Treatment Type: Bi-Hormonal, Insulin Only, Hybrid
3) End-User: Hospitals, Medical Centers, Other End-Users
Further subcategories break down device types as follows:
- Threshold Suspend Device Systems include insulin pumps with threshold suspend features and continuous glucose monitoring integrated systems
- Control-To-Range Systems cover hybrid closed-loop systems, insulin delivery systems with range control, and real-time glucose adjustment systems
- Control-To-Target Systems consist of fully closed-loop artificial pancreas systems, insulin pumps with targeted glucose control, and automated glucose regulation devices

This segmentation highlights the diversity of technologies and treatment approaches within the market, catering to a variety of clinical needs and patient preferences.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.